2026 SPS Seattle | Make Way for HER, Datopotamab Deruxtecan Use in Breast Cancer and Non-Small Cell Lung Cancer

2026 SPS Seattle | Make Way for HER, Datopotamab Deruxtecan Use in Breast Cancer and Non-Small Cell Lung Cancer

0% Complete

Course Content

Make Way for HER, Datopotamab Deruxtecan Use in Breast Cancer and Non-Small Cell Lung Cancer

This material is non-CME, no credits are available, and a certificate will not be provided upon completion.

Course Details

Duration
0.00 hour
Released
Oct 26, 2026
Last Review
Oct 26, 2026
Expires
Oct 26, 2029

Target Audience

Pharmacists
Pharmacy Technicians

Accreditation

N/A

Related Courses

2026 SPS Seattle | 505(b)(2): From Opportunity Assessment to Implementation Best Practices

2026 SPS Seattle | 505(b)(2): From Opportunity Assessment to Implementation Best Practices

0.00 Credits
1 Chapter
Pharmacology
Free
2026 SPS Seattle | HER’s First – Zongertinib’s Push to First-Line Setting in HER2 Positive Non-Small Cell Lung Cancer

2026 SPS Seattle | HER’s First – Zongertinib’s Push to First-Line Setting in HER2 Positive Non-Small Cell Lung Cancer

0.00 Credits
1 Chapter
Pharmacology
Free
Explore More Courses